Evidence-based treatment strategies for treatment-resistant bipolar depression: A systematic review

Bipolar Disorders

Volumn 15, Issue 1, 2013, Pages 61-69

  Sienaert, Pascal ^a   Lambrichts, Lore ^a   Dols, Annemiek ^b   De Fruyt, Jürgen ^c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c General Hospital St Jan   (Belgium)

Author keywords

Armodafinil; Bipolar disorder; Electroconvulsive therapy; Inositol; Ketamine; Lamotrigine; Modafinil; Pramipexole; Risperidone; Treatment resistance

Indexed keywords

ARMODAFINIL; CARBAMAZEPINE; GABAPENTIN; INOSITOL; KETAMINE; LAMOTRIGINE; LITHIUM; MODAFINIL; PLACEBO; PRAMIPEXOLE; RISPERIDONE; VALPROATE SEMISODIUM;

BIPOLAR DEPRESSION; BLOOD PRESSURE; CLINICAL TRIAL; DATA BASE; DISSOCIATION; DRUG EFFECT; DRUG TREATMENT FAILURE; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED PRACTICE; HUMAN; MEDLINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TACHYCARDIA; XEROSTOMIA;

ANTIMANIC AGENTS; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; EVIDENCE-BASED MEDICINE; HUMANS;

EID: 84872663272     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12026     Document Type: Review

References (87)

1. De Fruyt J, Demyttenaere K. Bipolar (spectrum) disorder and mood stabilization: standing at the crossroads? Psychother Psychosom 2007; 76: 77-88.
2. Hirschfeld RM, Vornik LA. Recognition and diagnosis of bipolar disorder. J Clin Psychiatry 2004; 65 (Suppl. 15): 5-9.
3. Bauer M, Ritter P, Grunze H, Pfennig A. Treatment options for acute depression in bipolar disorder. Bipolar Disord 2012; 14 (Suppl. 2): 37-50.
4. Judd LL, Akiskal HS, Schettler PJ et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59: 530-537.
5. Judd LL, Akiskal HS, Schettler PJ et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003; 60: 261-269.
6. Judd LL, Akiskal HS, Schettler PJ et al. Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry 2005; 62: 1322-1330.
7. De Fruyt J, Deschepper E, Audenaert K et al. Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis. J Psychopharmacology 2012; 26: 603-617.
8. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomized trials. Br J Psychiatry 2009; 194: 4-9.
9. Yatham LN, Calabrese JR, Kusumakar V. Bipolar depression: criteria for treatment selection, definition of refractoriness, and treatment options. Bipolar Disord 2003; 5: 85-97.
10. Sidor MM, MacQueen GM. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry 2011; 72: 156-167.
11. Sachs GS, Nierenberg AA, Calabrese JR et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007; 356: 1711-1722.
12. Ghaemi SN, Ko JY, Goodwin FK. The bipolar spectrum and the antidepressant view of the World. J Psychiatr Pract 2001; 7: 287-297.
13. Ghaemi SN, Ko JY, Goodwin FK. "Cade's disease" and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder. Can J Psychiatry 2002; 47: 125-134.
14. Vieta E, Colom F. Therapeutic options in treatment-resistant depression. Ann Med 2011; 43: 512-530.
15. Sachs GS. Treatment-resistant bipolar depression. Psychiatr Clin North Am 1996; 19: 215-236.
16. Gitlin M. Treatment-resistant bipolar disorder. Mol Psychiatry 2006; 11: 227-240.
17. Pacchiarotti I, Mazzarini L, Colom F et al. Treatment-resistant bipolar depression: towards a new definition. Acta Psychiatr Scand 2009; 120: 429-440.
18. Lipsman N, McIntyre RS, Giacobbe P, Torres C, Kennedy SH, Lozano AM. Neurosurgical treatment of bipolar depression: defining treatment resistance and identifying surgical targets. Bipolar Disord 2010; 12: 691-701.
19. Malhi GS, Bargh DM, Cashman E, Frye MA, Gitlin M. The clinical management of bipolar disorder complexity using a stratified model. Bipolar Disord 2012; 14 (Suppl. 2): 66-89.
20. Nivoli AMA, Colom F, Muru A et al. New treatment guidelines for acute bipolar depression: a systematic review. J Affect Disord 2011; 129: 14-26.
21. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004; 161: 564-566.
22. Nierenberg AA, Ostacher MJ, Calabrese JR et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 2006; 163: 210-216.
23. Diazgranados N, Ibrahim L, Brutsche NE et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010; 67: 793-802.
24. Zarate CA Jr, Brutsche NE, Ibrahim L et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012; 71: 939-946.
25. Frye MA, Grunze H, Suppes T et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry 2007; 164: 1242-1249.
26. Sienaert P, Vansteelandt K, Demyttenaere K, Peuskens J. Ultra-brief pulse ECT in bipolar and unipolar depressive disorder: differences in speed of response. Bipolar Disord 2009; 11: 418-424.
27. Bailine S, Fink M, Knapp R et al. Electroconvulsive therapy is equally effective in unipolar and bipolar depression. Acta Psychiatr Scand 2010; 121: 431-436.
28. Kellner CH, Knapp R, Husain MM et al. Bifrontal, bitemporal and right unilateral electrode placement in ECT: randomised trial. Br J Psychiatry 2010; 196: 226-234.
29. Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry 2007; 52: 46-54.
30. Parker G. The DSM classification of depressive disorders: debating its utility. Can J Psychiatry 2006; 51: 871-873.
31. Parker G. Antidepressants on trial: how valid is the evidence? Br J Psychiatry 2009; 194: 1-3.
32. Parker G. Classifying clinical depression: an operational proposal. Acta Psychiatry Scand 2011; 123: 314-316.
33. Maj J, Rogóz Z, Margas W et al. The effect of repeated treatment with pramipexole on the central dopamine D3 system. J Neural Transm 2000; 107: 1369-1379.
34. Zarate CA, Payne JL, Singh J et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004; 56: 54-60.
35. Goldberg JF, Frye MA, Dunn RT. Pramipexole in refractory bipolar depression. Am J Psychiatry 1999; 156: 798.
36. Sporn J, Ghaemi SN, Sambur MR et al. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry 2000; 12: 137-140.
37. Lattanzi L, Dell'Osso L, Cassano P et al. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord 2002; 4: 307-314.
38. Aiken CB. Pramipexole in psychiatry: a systematic review of the literature. J Clin Psychiatry 2007; 68: 1230-1236.
39. Hubble JP. Long-term studies of dopamine agonists. Neurology 2002; 58 (Suppl. 1): S42-S50.
40. Cephalon Inc. NUVIGIL (Armodafinil) Tablets (C-IV). Frazer, PA: Cephalon, Inc., 2008. Available from: http://www.nuvigil.com/media/Full_Prescribing_Information.pdf [accessed September 2009].
41. Beck P, Odle A, Wallace-Huitt T, Skinner RD, Garcia-Rill E. Modafinil increases arousal determined by P13 potential amplitude: an effect blocked by gap junction antagonists. Sleep 2008; 31: 1647-1654.
42. Urbano FJ, Leznik E, Llinás RR. Modafinil enhances thalamocortical activity by increasing neuronal electrotonic coupling. Proc Natl Acad Sci USA 2007; 104: 12554-12559.
43. Menza MA, Kaufman KR, Castellanos A. Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry 2000; 61: 378-381.
44. Fernandes PP, Petty F. Modafinil for remitted bipolar depression with hypersomnia. Ann Pharmacother 2003; 37: 1807-1809.
45. Hegerl U, Sander C, Olbrich S et al. Are psychostimulants a treatment option in mania? Pharmacopsychiatry 2009; 42: 169-174.
46. Schoenknecht P, Olbrich S, Sander C, Spindler P, Hegerl U. Treatment of acute mania with modafinil monotherapy. Biol Psychiatry 2010; 67: e55-e57.
47. Bschor T, Muller-Oerlinghausen B, Ulrich G. Decreased level of EEG-vigilance in acute mania as a possible predictor for a rapid effect of methylphenidate: a case study. Clin Electroencephalogr 2001; 32: 36-39.
48. Max JE, Richards L, Hamdan-Allen G. Case study: antimanic effectiveness of dextroamphetamine in a brain-injured adolescent. J Am Acad Child Adolesc Psychiatry 1995; 34: 472-476.
49. Clower CG. Treatment of mania with dextroamphetamine. J Clin Psychiatry 1988; 49: 283.
50. Garvey MJ, Hwang S, Teubnerrhodes D et al. Dextroamphetamine treatment of mania. J Clin Psychiatry 1987; 48: 412-413.
51. Brown WA, Mueller B. Alleviation of manic symptoms with catecholamine agonists. Am J Psychiatry 1979; 136: 230-231.
52. Kumar R. Approved and investigational uses of modafinil: an evidence-based review. Drugs 2008; 68: 1803-1839.
53. Chengappa KNR, Levine J, Gershon S et al. Inositol as an add-on treatment for bipolar depression. Bipolar Disord 2000; 2: 47-55.
54. Evins AE, Demopulos C, Yovel I et al. Inositol augmentation of lithium or valproate for bipolar depression. Bipolar Disord 2006; 8: 168-174.
55. Kusumakar V, Yatham LN. An open study of lamotrigine in refractory bipolar depression. Psychiatry Res 1997; 72: 145-148.
56. Calabrese JR, Bowden CL, McElroy SL et al. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiatry 1999; 156: 1019-1023.
57. Sharma V, Khan M, Corpse C. Role of lamotrigine in the management of treatment-resistant bipolar II depression: a chart review. J Affect Disord 2008; 111: 100-105.
58. Berman RM, Cappiello A, Anand A et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47: 351-354.
59. Zarate CA, Sing JB, Carlson PJ et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856-864.
60. Maeng S, Zarate CA, Du J et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008; 63: 349-352.
61. Law AJ, Deakin JF. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. NeuroReport 2001; 12: 2971-2974.
62. McCullumsmith RE, Kristiansen LV, Beneyto M, Scarr E, Dean B, Meador-Woodruff JH. Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. Brain Res 2007; 1127: 108-118.
63. Woo TU, Walsh JP, Benes FM. Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch Gen Psychiatry 2004; 61: 649-657.
64. Dierckx B, Heijnen WT, van den Broek WW, Birkenhager TK. Efficacy of electroconvulsive therapy in bipolar versus unipolar major depression: a meta-analysis. Bipolar Disord 2012; 14: 146-150.
65. Semkovska M, McLoughlin DM. Objective cognitive performance associated with electroconvulsive therapy for depression: a systematic review and meta-analysis. Biol Psychiatry 2010; 68: 568-577.
66. Sienaert P, Peuskens J. Electroconvulsive therapy: an effective therapy of medication-resistant bipolar disorder. Bipolar Disord 2006; 8: 304-306.
67. Sienaert P. What we have learned about electroconvulsive therapy and its relevance for the practicing psychiatrist. Can J Psychiatry 2011; 56: 5-12.
68. Kelly T, Lieberman D. The use of triiodothyronine as an augmentation agent in treatment-resistant bipolar II and bipolar disorder NOS. J Affect Disord 2009; 116: 222-226.
69. Bauer MS, Whybrow PC. Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Arch Gen Psychiatry 1990; 47: 435-440.
70. Ketter TA, Wang PW, Chandler RA et al. Adjunctive aripiprazole in treatment-resistant bipolar depression. Ann Clin Psychiatry 2006; 18: 169-172.
71. Kemp DE, Gilmer WS, Fleck J et al. Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisia. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 574-577.
72. Kemp DE, Dago PL, Straus JL et al. Aripiprazole augmentation for treatment-resistant bipolar depression: sustained remission after 36months. J Clin Psychopharmacology 2007; 27: 304-305.
73. Benedetti F, Barbini B, Fulgosi MC et al. Combined Total sleep deprivation and light therapy in the treatment of drug-resistant bipolar depression: acute response and long-term remission rates. J Clin Psychiatry 2005; 66: 1535-1540.
74. Beauchemin KM, Hays P. Phototherapy is a useful adjunct in the treatment of depressed in-patients. Acta Psychiatr Scand 1997; 95: 424-427.
75. George MS, Nahas Z, Molloy M et al. A controlled trial of daily left prefrontal cortex TMS for treating depression. Biol Psychiatry 2000; 48: 962-970.
76. Dell'Osso B, Mundo E, D'Urso N et al. Augmentative repetitive navigated transcranial magnetic stimulation (rTMS) in drug-resistant bipolar depression. Bipolar Disord 2009; 11: 76-81.
77. Fitzgerald PB, Huntsman S, Gunewardene R et al. A randomized trial of low-frequency right prefrontal-cortex transcranial magnetic stimulation as augmentation in treatment-resistant major depression. Int J Neuropsychopharmacology 2006; 9: 655-666.
78. Dell'Osso B, Dario A, Ciabatti M et al. Vagus nerve stimulation in treatment-resistant bipolar depression. Clinical Neuropsychiatry 2009; 6: 252-258.
79. Rush AJ, Marangell LB, Sackeim HA et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005; 58: 347-354.
80. Nierenberg AA, Alpert JE, Gardner-Schuster EE et al. Vagus nerve stimulation: 2-year outcomes for bipolar versus unipolar treatment-resistant depression. Biol Psychiatry 2008; 64: 455-460.
81. Rush AJ, Sackeim HA, Marangell LB et al. Effects of 12months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry 2005; 58: 355-363.
82. Cristancho P, Cristancho MA, Baltuch GH et al. Effectiveness and safety of vagus nerve stimulation for severe treatment-resistant major depression in clinical practice after FDA approval: outcomes at 1year. J Clin Psychiatry 2011; 72: 1376-1382.
83. Frye MA, Ketter TA, Kimbrell TA et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20: 607-614.
84. Kranaster L, Kammerer-Ciernioch J, Hoyer C, Sartorius A. Clinically favorable effects of ketamine as anaesthetic for electroconvulsive therapy: a retrospective study. Eur Arch Psychiatry Clin Neurosci 2011; 261: 575-582.
85. Loo C, Simpson B, MacPherson R. Augmentation strategies in electroconvulsive therapy. J ECT 2010; 26: 202-207.
86. Okamoto N, Nakai T, Sakamoto K et al. Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia. J ECT 2010; 26: 223-227.
87. Wang X, Chen Y, Zhou X, Liu F, Zhang T, Zhang C. Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder. J ECT 2012; 28: 128-132.